| 8.93 0.64 (7.72%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.26 | 1-year : | 12.62 |
| Resists | First : | 9.64 | Second : | 10.81 |
| Pivot price | 8.59  |
|||
| Supports | First : | 7.75 | Second : | 6.44 |
| MAs | MA(5) : | 8.43 |
MA(20) : | 8.96 |
| MA(100) : | 8.24 |
MA(250) : | 6.83 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.2 |
D(3) : | 19.3 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 12.43 | Low : | 1.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IBRX ] has closed below upper band by 34.0%. Bollinger Bands are 11.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.97 - 9.01 | 9.01 - 9.05 |
| Low: | 8.11 - 8.15 | 8.15 - 8.2 |
| Close: | 8.85 - 8.93 | 8.93 - 9.01 |
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Wed, 04 Nov 2026
A bladder cancer treatment reaches its first European patients in Germany and Austria - Stock Titan
Tue, 27 Oct 2026
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave - Yahoo Finance
Fri, 09 Oct 2026
Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement - TradingKey
Fri, 02 Oct 2026
Immunitybio Inc Stock (IBRX) Moved Up by 9.64% on Oct 2: What Investors Need To Know - TradingKey
Wed, 30 Sep 2026
Immunitybio Inc Stock (IBRX) Moved Up by 11.15% on Sep 30: What Signal Does It Send? - TradingKey
Tue, 22 Sep 2026
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1,060 (M) |
| Shares Float | 407 (M) |
| Held by Insiders | 62.1 (%) |
| Held by Institutions | 19.7 (%) |
| Shares Short | 124,090 (K) |
| Shares Short P.Month | 125,640 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1 |
| Profit Margin | 0 % |
| Operating Margin | -120.5 % |
| Return on Assets (ttm) | -30.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 93.9 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -281 (M) |
| Levered Free Cash Flow | -187 (M) |
| PE Ratio | -9.31 |
| PEG Ratio | 0 |
| Price to Book value | -9.03 |
| Price to Sales | 57.09 |
| Price to Cash Flow | -33.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|